(CX) Cemex SAB de CV - Overview
Exchange: NYSE •
Country: Mexico •
Currency: USD •
Type: Common Stock •
ISIN: US1512908898
Stock: Cement, Concrete, Aggregates, Building Materials, Construction Services
Total Rating 52
Risk 64
Buy Signal -0.88
| Risk 5d forecast | |
|---|---|
| Volatility | 45.8% |
| Relative Tail Risk | -2.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.75 |
| Alpha | 57.78 |
| Character TTM | |
|---|---|
| Beta | 1.095 |
| Beta Downside | 0.514 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.37% |
| CAGR/Max DD | 0.70 |
EPS (Earnings per Share)
Revenue
Description: CX Cemex SAB de CV March 05, 2026
Cemex SAB de CV (CX) produces and sells cement, ready-mix concrete, aggregates, and other construction materials globally. The company offers a diverse product portfolio including various cement types, specialized concrete mixes, crushed stone, and sand.
In addition to material sales, Cemex provides logistics, transportation, and waste management services. The construction materials sector is cyclical, influenced by economic growth and infrastructure spending. Vertical integration, from raw material extraction to product delivery, is common in this industry.
Cemex also focuses on sustainable solutions, such as Vertua products and recycling construction waste. Understanding the companys operational efficiency and market share within its key geographies is crucial. For deeper analysis, consider ValueRays comprehensive company profiles.
Headlines to watch out for
- Infrastructure spending drives cement and concrete demand
- Energy costs impact production profitability
- Mexican peso volatility affects earnings
- Global construction slowdown reduces sales volume
- Regulatory environmental compliance increases operating expenses
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 963.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.22 > 1.0 |
| NWC/Revenue: -7.95% < 20% (prev -6.64%; Δ -1.31% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.06b > Net Income 963.2m |
| Net Debt (5.83b) to EBITDA (2.54b): 2.29 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.9m) vs 12m ago -97.00% < -2% |
| Gross Margin: 31.41% > 18% (prev 0.33%; Δ 3.11k% > 0.5%) |
| Asset Turnover: 57.53% > 50% (prev 59.34%; Δ -1.82% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBITDA TTM 2.54b / Interest Expense TTM 543.6m) |
Altman Z'' 1.10
| A: -0.04 (Total Current Assets 6.10b - Total Current Liabilities 7.38b) / Total Assets 28.97b |
| B: 0.21 (Retained Earnings 6.08b / Total Assets 28.97b) |
| C: 0.04 (EBIT TTM 1.25b / Avg Total Assets 28.13b) |
| D: 0.39 (Book Value of Equity 5.93b / Total Liabilities 15.34b) |
| Altman-Z'' Score: 1.10 = BB |
Beneish M -2.57
| DSRI: 1.62 (Receivables 2.56b/1.58b, Revenue 16.18b/16.20b) |
| GMI: 1.05 (GM 31.41% / 32.89%) |
| AQI: 0.91 (AQ_t 0.37 / AQ_t-1 0.40) |
| SGI: 1.00 (Revenue 16.18b / 16.20b) |
| TATA: -0.04 (NI 963.2m - CFO 2.06b) / TA 28.97b) |
| Beneish M-Score: -2.57 (Cap -4..+1) = A |
What is the price of CX shares?
As of March 15, 2026, the stock is trading at USD 10.61 with a total of 10,729,893 shares traded.
Over the past week, the price has changed by -4.47%, over one month by -17.01%, over three months by -10.53% and over the past year by +79.06%.
Over the past week, the price has changed by -4.47%, over one month by -17.01%, over three months by -10.53% and over the past year by +79.06%.
Is CX a buy, sell or hold?
Cemex SAB de CV has received a consensus analysts rating of 3.79.
Therefor, it is recommend to hold CX.
- StrongBuy: 3
- Buy: 6
- Hold: 4
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.6 | 27.9% |
| Analysts Target Price | 13.6 | 27.9% |
CX Fundamental Data Overview March 12, 2026
P/E Trailing = 39.8519
P/E Forward = 14.9925
P/S = 0.9677
P/B = 1.1896
P/EG = 0.3877
Revenue TTM = 16.18b USD
EBIT TTM = 1.25b USD
EBITDA TTM = 2.54b USD
Long Term Debt = 4.46b USD (from longTermDebt, last quarter)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 7.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.83b USD (from netDebt column, last quarter)
Enterprise Value = 21.44b USD (15.61b + Debt 7.65b - CCE 1.82b)
Interest Coverage Ratio = 2.29 (Ebit TTM 1.25b / Interest Expense TTM 543.6m)
EV/FCF = 21.23x (Enterprise Value 21.44b / FCF TTM 1.01b)
FCF Yield = 4.71% (FCF TTM 1.01b / Enterprise Value 21.44b)
FCF Margin = 6.24% (FCF TTM 1.01b / Revenue TTM 16.18b)
Net Margin = 5.95% (Net Income TTM 963.2m / Revenue TTM 16.18b)
Gross Margin = 31.41% ((Revenue TTM 16.18b - Cost of Revenue TTM 11.10b) / Revenue TTM)
Gross Margin QoQ = 26.96% (prev 33.58%)
Tobins Q-Ratio = 0.74 (Enterprise Value 21.44b / Total Assets 28.97b)
Interest Expense / Debt = 1.99% (Interest Expense 152.4m / Debt 7.65b)
Taxrate = 48.78% (386.2m / 791.9m)
NOPAT = 638.0m (EBIT 1.25b * (1 - 48.78%))
Current Ratio = 0.83 (Total Current Assets 6.10b / Total Current Liabilities 7.38b)
Debt / Equity = 0.57 (Debt 7.65b / totalStockholderEquity, last quarter 13.31b)
Debt / EBITDA = 2.29 (Net Debt 5.83b / EBITDA 2.54b)
Debt / FCF = 5.77 (Net Debt 5.83b / FCF TTM 1.01b)
Total Stockholder Equity = 13.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.42% (Net Income 963.2m / Total Assets 28.97b)
RoE = 7.22% (Net Income TTM 963.2m / Total Stockholder Equity 13.34b)
RoCE = 7.00% (EBIT 1.25b / Capital Employed (Equity 13.34b + L.T.Debt 4.46b))
RoIC = 4.78% (NOPAT 638.0m / Invested Capital 13.34b)
WACC = 7.01% (E(15.61b)/V(23.26b) * Re(9.95%) + D(7.65b)/V(23.26b) * Rd(1.99%) * (1-Tc(0.49)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -68.38%
[DCF] Terminal Value 81.45% ; FCFF base≈1.01b ; Y1≈980.3m ; Y5≈976.4m
[DCF] Fair Price = 10.71 (EV 21.37b - Net Debt 5.83b = Equity 15.54b / Shares 1.45b; r=7.01% [WACC]; 5y FCF grow -4.15% → 2.90% )
EPS Correlation: 35.81 | EPS CAGR: 17.76% | SUE: 0.19 | # QB: 0
Revenue Correlation: 24.57 | Revenue CAGR: 3.02% | SUE: 0.39 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.22 | Chg7d=+0.000 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=0.80 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=-1 | Growth EPS=+53.8% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=0.96 | Chg7d=+0.003 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+20.4% | Growth Revenue=+3.5%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.4% (Discount Rate 9.9% - Earnings Yield 2.5%)
[Growth] Growth Spread = -1.8% (Analyst 5.7% - Implied 7.4%)
P/E Forward = 14.9925
P/S = 0.9677
P/B = 1.1896
P/EG = 0.3877
Revenue TTM = 16.18b USD
EBIT TTM = 1.25b USD
EBITDA TTM = 2.54b USD
Long Term Debt = 4.46b USD (from longTermDebt, last quarter)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 7.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.83b USD (from netDebt column, last quarter)
Enterprise Value = 21.44b USD (15.61b + Debt 7.65b - CCE 1.82b)
Interest Coverage Ratio = 2.29 (Ebit TTM 1.25b / Interest Expense TTM 543.6m)
EV/FCF = 21.23x (Enterprise Value 21.44b / FCF TTM 1.01b)
FCF Yield = 4.71% (FCF TTM 1.01b / Enterprise Value 21.44b)
FCF Margin = 6.24% (FCF TTM 1.01b / Revenue TTM 16.18b)
Net Margin = 5.95% (Net Income TTM 963.2m / Revenue TTM 16.18b)
Gross Margin = 31.41% ((Revenue TTM 16.18b - Cost of Revenue TTM 11.10b) / Revenue TTM)
Gross Margin QoQ = 26.96% (prev 33.58%)
Tobins Q-Ratio = 0.74 (Enterprise Value 21.44b / Total Assets 28.97b)
Interest Expense / Debt = 1.99% (Interest Expense 152.4m / Debt 7.65b)
Taxrate = 48.78% (386.2m / 791.9m)
NOPAT = 638.0m (EBIT 1.25b * (1 - 48.78%))
Current Ratio = 0.83 (Total Current Assets 6.10b / Total Current Liabilities 7.38b)
Debt / Equity = 0.57 (Debt 7.65b / totalStockholderEquity, last quarter 13.31b)
Debt / EBITDA = 2.29 (Net Debt 5.83b / EBITDA 2.54b)
Debt / FCF = 5.77 (Net Debt 5.83b / FCF TTM 1.01b)
Total Stockholder Equity = 13.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.42% (Net Income 963.2m / Total Assets 28.97b)
RoE = 7.22% (Net Income TTM 963.2m / Total Stockholder Equity 13.34b)
RoCE = 7.00% (EBIT 1.25b / Capital Employed (Equity 13.34b + L.T.Debt 4.46b))
RoIC = 4.78% (NOPAT 638.0m / Invested Capital 13.34b)
WACC = 7.01% (E(15.61b)/V(23.26b) * Re(9.95%) + D(7.65b)/V(23.26b) * Rd(1.99%) * (1-Tc(0.49)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -68.38%
[DCF] Terminal Value 81.45% ; FCFF base≈1.01b ; Y1≈980.3m ; Y5≈976.4m
[DCF] Fair Price = 10.71 (EV 21.37b - Net Debt 5.83b = Equity 15.54b / Shares 1.45b; r=7.01% [WACC]; 5y FCF grow -4.15% → 2.90% )
EPS Correlation: 35.81 | EPS CAGR: 17.76% | SUE: 0.19 | # QB: 0
Revenue Correlation: 24.57 | Revenue CAGR: 3.02% | SUE: 0.39 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.22 | Chg7d=+0.000 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=0.80 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=-1 | Growth EPS=+53.8% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=0.96 | Chg7d=+0.003 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+20.4% | Growth Revenue=+3.5%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.4% (Discount Rate 9.9% - Earnings Yield 2.5%)
[Growth] Growth Spread = -1.8% (Analyst 5.7% - Implied 7.4%)